ImmunoPrecise Antibodies Ltd. (IPA) Q2 2025 Earnings Call Transcript

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q2 2025 Earnings Conference Call December 10, 2024 10:30 AM ET

Company Participants

Jennifer Bath – CEO
Kristin Taylor – CFO

Conference Call Participants

Swayampakula Ramakanth – H.C. Wainwright
William McHale – Ingalls & Snyder

Operator

Good morning, ladies and gentlemen, and thank you for joining us today for ImmunoPrecise Antibodies Second Quarter Fiscal Year 2025 Earnings Call. We appreciate your time and interest in IPA.

Today’s call will be led by our CEO, Dr. Jennifer Bath; and our CFO, Kristin Taylor. They will provide a review of our financial performance, strategic initiatives and key operational highlights for the quarter.

Please note that a copy of today’s presentation, along with our financial statements will be available on our company website for your reference. We encourage you to review these materials to gain a deeper understanding of our performance and strategic direction. Once again, thank you for joining us today. We look forward to sharing our progress and discussing our future plans with you.

Before we proceed, I would like to remind everyone that today’s discussion will contain forward-looking statements. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially from those anticipated due to various factors, including, but not limited to changes in market conditions, regulatory changes and other unforeseen business risks. Please note that these forward-looking statements are made as of today and we undertake no obligation to update them as a result of new information or future events unless required by law. We strongly advise all participants to refer to our filings with the Securities and Exchange Commission, SEC, including our most recent Form 20-F, and other periodic reports, for a more detailed discussion of these risks and uncertainties and for a more complete understanding of the risks inherent in our business operations and the